J Pediatr Infect Dis 2021; 16(01): 007-011
DOI: 10.1055/s-0040-1718882
Original Article

Follow-up Brucellacapt and Rose Bengal Tests in 110 Children with Brucellosis

Sevliya Öcal Demir
1  Department of Pediatric Health and Diseases, İstanbul Medeniyet University Göztepe Research and Training Hospital, İstanbul, Turkey
,
Fatma Bacalan
2  Department of Medical Microbiology, Diyarbakir Children's Hospital, Diyarbakir, Turkey
› Author Affiliations
Funding None.

Abstract

Objective The interpretation of serologic tests in brucellosis can be difficult because of nonspecific symptoms and vague signs of disease, and limitations of serological tests to distinguish persistent and cleared infection. Here, we evaluated the role of Brucellacapt test in conjunction with Rose Bengal test (RBT) in the follow-up of children treated for brucellosis.

Methods A total of 174 children diagnosed with brucellosis were included in the study. Data about demographic characteristics of patients, clinical and laboratory findings including Brucellacapt and RBT results, therapeutic approach, and response to treatment were collected from medical records.

Results Of the 174 cases, 109 (62.6%) were boys and 65 (37.4%) were girls. The mean age of children at the diagnosis was 122 ± 54 months. Sixty-four cases were excluded from the study for loss to follow-up. The follow-up period for the remained 110 cases was 4.3 ± 2.9 months. Eleven cases (10%) had persistent illness, 7 (6.4%) had recurrence/relapse, and 92 had favorable outcome. During the follow-up, Brucellacapt titers did not drop under 1/320 in cases with persistent illness, and it increased again to 1/320 in cases with relapses at average 6.1 months after treatment. In 48 of cases with favorable outcome, Brucellacapt titers decreased to 1/160 in average 3.3 ± 1.8 months; in 35 cases, RBT became negative in average 3.8 ± 2.5 months, and there was no statistically significant difference between them (p = 0.241). In cases with higher Brucellacapt titers on admission, decrement of titers took longer time.

Conclusion Persistent serological titers without clinical findings of brucellosis should not lead physician to prolong or repeat treatment because the decline in Brucellacapt titers and RBT negativity may be delayed in contrast to clinical recovery.

Ethical Approval

The study was approved by the decision of Clinical Research Ethics Committee of Health Sciences University Diyarbakır Gazi Yaşargil Training and Research Hospital with the number of 325, Jun 14, 2019.


Availability of Data and Materials

The dataset used and analyzed during this study are available from the corresponding author on reasonable request.




Publication History

Received: 04 May 2020

Accepted: 15 September 2020

Publication Date:
02 November 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany